Amgen Inc. (AMGN )

Currency in USD Disclaimer

$292.31 -$1.81 (-0.62%)

Open 10/07/2025

Day's Range

$290.21

$293.62

52 wk Range

$253.3

$335.88

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Symbol AMGN
Company Amgen Inc.
Price $292.31
Changes Percentage -0.62
Change -1.8142
Day Low $290.21
Day High $293.62
Year High $335.88
Year Low $253.3
Market Cap $157,384,703,521
Price Avg 50 EMA (D) $287.47
Price Avg 200 EMA (D) $288.27
Exchange NASDAQ
Volume 159,671
Average Volume 2,604,434
Open $293.28
Previous Close $294.12
EPS 12.24
PE 23.88
Earnings Announcement 2025-11-04 20:00:00
Shares Outstanding $538,361,851

Company brief: AMGEN INC. (AMGN )

Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Robert A. Bradway
Website https://www.amgen.com
Headquarters US
Employees (FY) N/A
Founded 06-17-1983
ISIN US0311621009

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.